MSNJ’s Delegation to the AMA Fosters New Policy on Drug Shortages
MSNJ’s delegation to the American Medical Association attended its Annual House of Delegates meeting last month in Chicago. The AMA House of Delegates considered several resolutions submitted by the New Jersey delegation. As a result of testimony by MSNJ’s leadership, as well as support from a number of other state delegations, the AMA created a new policy concerning national drug shortages.
The new policy will require manufacturers of FDA approved drugs to give the agency at least six months advanced notice, or as soon as practicable, of anticipated discontinuance of the manufacture or marketing of a product. The policy also supports the creation of a task force to enhance the HHS Secretary’s response to preventing and mitigating drug shortages and to create a strategic plan to address ongoing aspects of drug shortages. The AMA has pursued federal legislation over the past year, due in part to MSNJ’s advocacy on this issue.
The AMA House of Delegates also combined MSNJ’s resolution on the Sunshine Act with that of the Nevada delegation adopting a substitute resolution that requires the AMA to continue efforts to minimize the burden and CMS’s unauthorized expansion of the Sunshine Act. It also requires AMA to work with CMS to create a physician comment section on the “Physician Payments Sunshine Act” public database.